-
Product Insights
NewLikelihood of Approval Analysis for Disruptive Behavior Disorder
Overview How likely is it that the drugs in Disruptive Behavior Disorder will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Disruptive Behavior Disorder Overview Disruptive Behavior Disorders (DBD) encompass conditions like...
-
Company Insights
Innovation and Patenting activity of CD Projekt RED SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CD Projekt RED SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD-388 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Seasonal Influenza Drug Details:CD-388 is under development for the treatment and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD-388 in Pandemic Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Pandemic Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Pandemic InfluenzaDrug Details:CD-388 is under development for the treatment and prevention...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD-388 in Influenzavirus B Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD-388 in Influenzavirus B Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CD-388 in Influenzavirus B Infections Drug Details:CD-388 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone Hydrochloride in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Sarcomas Drug Details: AGEN-2373 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Breast Cancer Drug Details: AGEN-2373 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Systemic Sclerosis (Scleroderma) Drug Details: KYV-101 is under development...